Compounds that inhibit main protease of SARS-CoV-2 discovered
Using high-throughput screening techniques, researchers have identified two families of active substances that block SARS-CoV-2 replication.
List view / Grid view
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.
Using high-throughput screening techniques, researchers have identified two families of active substances that block SARS-CoV-2 replication.
26 February 2021 | By Domain Therapeutics
Watch our on-demand webinar which focused on the progress achieved in G protein-coupled receptor (GPCR) therapeutic antibody-based discovery and development.
A new compound can inhibit the build-up of plaque in arteries and prevent atherosclerosis, researchers have shown.
According to a new report, the high-throughput screening market will increase at a CAGR of 11.5 percent from 2020 to 2025.
Researchers have developed a workflow to study the behaviour of C. elegans in a high-throughput screen to identify Parkinson's disease drugs.
Between January and October 2020, scientists globally have published more than 87,000 papers about the coronavirus.
Scientists have developed a compound that stops the degeneration of upper motor neurons, a contributor to amyotrophic lateral sclerosis (ALS).
Discover the latest in SARS-CoV-2 antibody research as we cover three of the most recent developments in this article.
A team has shown that STING activation is a new molecular target in the fight against graft-versus-host disease (GVHD).
In a zebrafish model, researchers have found that the protein NAPMT can trigger muscle stem cells to proliferate and heal muscle damage.
This whitepaper describes the automated culturing of hiPSC-derived cells for high-throughput phenotypic screening, using validated phenotypic assays.
New research has shown that 'hidden' lysis genes in bacteriophages could be used in the development of a new class of antibiotics.
Jim Shanahan from SynDevRx explains why metabo-oncology treatment modalities could be the answer to a rise in metabolic disorders and cancers.
Researchers have discovered that thapsigargin has novel antiviral properties and is effective against COVID-19 in pre-clinical studies.
A new protein can trick SARS-CoV-2 and bind to the Spike protein rather than cell membranes in a kidney organoid.